News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Would Pfizer Inc. Buy King Pharmaceuticals®, Inc.? King Gains on Takeover Speculation
August 6, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Aug. 5 (Bloomberg) -- King Pharmaceuticals Inc.'s call- option trading was the busiest since 2004 and its shares rose to an 11-month high on speculation Pfizer Inc., the biggest U.S. drugmaker by market value, will buy the company.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Pfizer
MORE ON THIS TOPIC
Immuno-oncology
Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset
October 28, 2026
·
2 min read
·
Tristan Manalac
Earnings
Biogen notches 3rd straight quarter of growth thanks to newer products, Apellis
October 28, 2026
·
1 min read
·
Annalee Armstrong
Podcast
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
October 28, 2026
·
1 min read
·
Jef Akst
Business
US biotechs take lion’s share of $54.5B VC money raised since 2025
October 26, 2026
·
1 min read
·
Gabrielle Masson